Comparison of EGFR mutation detection between the tissue and cytology using direct sequencing, pyrosequencing and peptide nucleic acid clamping in lung adenocarcinoma: Korean multicentre study

QJM: An International Journal of Medicine

Volumn 109, Issue 3, 2016, Pages 167-173

  Min, Kyueng Whan ^a   Kim, Wan Seop ^a   Jang, Se Jin ^b   Choi, Yoo Duk ^c   Chang, Sunhee ^d   Jung, Soon Hee ^e   Kim, Lucia ^f   Roh, Mee Sook ^g   Lee, Choong Sik ^h   Shim, Jung Weon ⁱ   Kim, Mi Jin ^j   Lee, Geon Kook ^k  

^a Konkuk University School of Medicine   (South Korea)

^b Asan Medical Center   (South Korea)

^c Chonnam National University Medical School   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e Yonsei University Wonju College of Medicine   (South Korea)

^f Inha University School of Medicine   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h Chungnam National University College of Medicine   (South Korea)

ⁱ Hallym University College of Medicine   (South Korea)

^j Yeungnam University College of Medicine   (South Korea)

^k National Cancer Center   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PEPTIDE NUCLEIC ACID; DNA; EGFR PROTEIN, HUMAN;

ARTICLE; CYTOLOGY; EXON; FEMALE; GENE MUTATION; GENETIC PROCEDURES; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERMETHOD COMPARISON; KOREA; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PEPTIDE NUCLEIC ACID CLAMPING; PRIORITY JOURNAL; PYROSEQUENCING; TUMOR BIOPSY; ADENOCARCINOMA; AGED; BIOPSY; CLINICAL TRIAL; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; DNA SEQUENCE; EVALUATION STUDY; GENETICS; LUNG TUMOR; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; SPECIMEN HANDLING; VERY ELDERLY;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; BIOPSY; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PEPTIDE NUCLEIC ACIDS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA; SPECIMEN HANDLING;

EID: 84960449439     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcv103     Document Type: Article

References (25)

1. Azzoli CG, Baker S, Jr., Temin S, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. Zhongguo Fei Ai Za Zhi 2010; 13:171-89.
2. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010; 362:2380-8.
3. Pao W, Ladanyi M. Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method. Clin Cancer Res 2007; 13:4954-5.
4. Langaee T, Ronaghi M. Genetic variation analyses by Pyrosequencing. Mutat Res 2005; 573:96-102.
5. Ahmadian A, Ehn M, Hober S. Pyrosequencing: history, biochemistry and future. Clin Chim Acta 2006; 363:83-94.
6. Dufort S, Richard MJ, Lantuejoul S, de Fraipont F. Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC. J Exp Clin Cancer Res 2011; 30:57.
7. Dufort S, Richard MJ, de Fraipont F. Pyrosequencing method to detect KRAS mutation in formalin-fixed and paraffinembedded tumor tissues. Anal Biochem 2009; 391:166-8.
8. Kim SK, Kim DL, Han HS, et al. Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules. Diagn Mol Pathol 2008; 17:118-25.
9. Marchetti A, Milella M, Felicioni L, et al. Clinical implications of KRAS mutations in lung cancer patients treated with tyrosine kinase inhibitors: an important role for mutations in minor clones. Neoplasia 2009; 11:1084-92.
10. Kim HJ, Lee KY, Kim YC, et al. Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Lung Cancer 2012; 75:321-5.
11. da Cunha Santos G, Saieg MA, Geddie W, Leighl N. EGFR gene status in cytological samples of nonsmall cell lung carcinoma: controversies and opportunities. Cancer Cytopathol 2011; 119:80-91.
12. Asano H, Toyooka S, Tokumo M, et al. Detection of EGFR gene mutation in lung cancer by mutant-enriched polymerase chain reaction assay. Clin Cancer Res 2006; 12:43-8.
13. Nakajima T, Yasufuku K, Nakagawara A, Kimura H, Yoshino I. Multigene mutation analysis of metastatic lymph nodes in non-small cell lung cancer diagnosed by endobronchial ultrasound-guided transbronchial needle aspiration. Chest 2011; 140:1319-24.
14. Kawahara A, Azuma K, Sumi A, et al. Identification of nonsmall-cell lung cancer with activating EGFR mutations in malignant effusion and cerebrospinal fluid: rapid and sensitive detection of exon 19 deletion E746-A750 and exon 21 L858R mutation by immunocytochemistry. Lung Cancer 2011; 74:35-40.
15. Kimura H, Fujiwara Y, Sone T, et al. EGFR mutation status in tumour-derived DNA frompleural effusion fluid is a practical basis for predicting the response to gefitinib. Br J Cancer 2006; 95:1390-5.
16. Lozano MD, Zulueta JJ, Echeveste JI, et al. Assessment of epidermal growth factor receptor and K-ras mutation status in cytological stained smears of non-small cell lung cancer patients: correlation with clinical outcomes. Oncologist 2011; 16:877-85.
17. Tsai TH, Wu SG, Chang YL, et al. Effusion immunocytochemistry as an alternative approach for the selection of first-line targeted therapy in advanced lung adenocarcinoma. J Thorac Oncol 2012; 7:993-1000.
18. Yang JC, Wu YL, Chan V, et al. Epidermal growth factor receptor mutation analysis in previously unanalyzed histological samples and cytology samples from the phase III Iressa Pan-ASia Study (IPASS). Lung Cancer 2013; 83:174-81.
19. Stigt JA, tHart NA, Knol AJ, Uil SM, Groen HJ. Pyrosequencing analysis of EGFR and KRAS mutations in EUS and EBUSderived cytologic samples of adenocarcinomas of the lung. J Thorac Oncol 2013; 8:1012-8.
20. Lee HJ, Xu X, Kim H, et al. Comparison of Direct Sequencing, PNA Clamping-Real Time Polymerase Chain Reaction, and Pyrosequencing Methods for the Detection of EGFR Mutations in Non-small Cell Lung Carcinoma and the Correlation with Clinical Responses to EGFR Tyrosine Kinase Inhibitor Treatment. Korean J Pathol 2013; 47:52-60.
21. Schuurbiers OC, Looijen-Salamon MG, Ligtenberg MJ, van der Heijden HF. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound-and endobronchial ultrasound-guided fine needle cytological aspirates. J Thorac Oncol 2010; 5:1664-7.
22. Zhuang YP, Wang HY, Shi MQ, Zhang J, Feng Y. Use of CTguided fine needle aspiration biopsy in epidermal growth factor receptor mutation analysis in patients with advanced lung cancer. Acta Radiol 2011; 52:1083-7.
23. Khode R, Larsen DA, Culbreath BC, et al. Comparative study of epidermal growth factor receptor mutation analysis on cytology smears and surgical pathology specimens from primary and metastatic lung carcinomas. Cancer Cytopathol 2013; 121:361-9.
24. Goto K, Satouchi M, Ishii G, et al. An evaluation study of EGFR mutation tests utilized for non-small-cell lung cancer in the diagnostic setting. Ann Oncol 2012; 23:2914-9.
25. Sakurada A, Lara-Guerra H, Liu N, Shepherd FA, Tsao MS. Tissue heterogeneity of EGFR mutation in lung adenocarcinoma. J Thorac Oncol 2008; 3:527-9.